[go: up one dir, main page]

NO2970700T3 - - Google Patents

Info

Publication number
NO2970700T3
NO2970700T3 NO14709546A NO14709546A NO2970700T3 NO 2970700 T3 NO2970700 T3 NO 2970700T3 NO 14709546 A NO14709546 A NO 14709546A NO 14709546 A NO14709546 A NO 14709546A NO 2970700 T3 NO2970700 T3 NO 2970700T3
Authority
NO
Norway
Application number
NO14709546A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2970700T3 publication Critical patent/NO2970700T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14709546A 2012-12-13 2014-03-05 NO2970700T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
NO2970700T3 true NO2970700T3 (fr) 2018-05-26

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14709546A NO2970700T3 (fr) 2012-12-13 2014-03-05

Country Status (44)

Country Link
US (1) US9211288B2 (fr)
EP (1) EP2931276B1 (fr)
JP (1) JP6257641B2 (fr)
KR (1) KR102171152B1 (fr)
CN (1) CN104853755B (fr)
AP (1) AP2015008498A0 (fr)
AR (2) AR093939A1 (fr)
AU (1) AU2013357308B2 (fr)
BR (1) BR112015013675B1 (fr)
CA (1) CA2893468C (fr)
CL (1) CL2015001615A1 (fr)
CR (1) CR20150303A (fr)
CY (1) CY1120098T1 (fr)
DK (1) DK2931276T3 (fr)
DO (1) DOP2015000133A (fr)
EA (1) EA028300B1 (fr)
EC (1) ECSP15023182A (fr)
ES (1) ES2663680T3 (fr)
GE (1) GEP201706739B (fr)
GT (1) GT201500143A (fr)
HR (1) HRP20180333T1 (fr)
HU (1) HUE036280T2 (fr)
IL (1) IL239192B (fr)
LT (1) LT2931276T (fr)
MA (1) MA38253B1 (fr)
ME (1) ME03029B (fr)
MX (1) MX362886B (fr)
MY (1) MY171802A (fr)
NI (1) NI201500078A (fr)
NO (1) NO2970700T3 (fr)
NZ (1) NZ708595A (fr)
PE (1) PE20151026A1 (fr)
PH (1) PH12015501302A1 (fr)
PL (1) PL2931276T3 (fr)
PT (1) PT2931276T (fr)
RS (1) RS56949B1 (fr)
RU (1) RU2635528C2 (fr)
SG (1) SG11201504483YA (fr)
SI (1) SI2931276T1 (fr)
SM (1) SMT201800135T1 (fr)
TN (1) TN2015000235A1 (fr)
UA (1) UA114016C2 (fr)
WO (1) WO2014090929A1 (fr)
ZA (1) ZA201504274B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
US10493046B2 (en) * 2015-07-17 2019-12-03 Universite Paris Descartes 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药(厦门)有限公司 一种沃替西汀口腔崩解片及其制备方法
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
JP6801129B2 (ja) * 2017-03-30 2020-12-16 ランドル リサーチ,エルエルシー うつ病の治療方法
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (fr) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Dérivés de quinoléine
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
KR100195399B1 (ko) 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
BR9708655A (pt) 1996-04-12 1999-08-03 Hoechst Marion Roussel Inc Derivados de isatina como inibidores de acetilcolinesterase e analgésicos
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1491531B1 (fr) 2002-03-29 2007-12-26 Eisai R&D Management Co., Ltd. Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine)
ES2314200T3 (es) * 2002-05-31 2009-03-16 H. Lundbeck A/S Una combinacion de un antagonista de nmda e inhibidores de esterasa de acetilcolina par ael tratamiento de la enfermedad de alzheimer.
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101460156B (zh) * 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
JP2009539850A (ja) * 2006-06-09 2009-11-19 ワイス 認知機能を増強する方法
AR061481A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a
WO2009005519A1 (fr) * 2007-06-29 2009-01-08 Accera, Inc. Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
TN2015000235A1 (en) 2016-10-03
KR102171152B1 (ko) 2020-10-29
SMT201800135T1 (it) 2018-05-02
CA2893468C (fr) 2021-01-12
CR20150303A (es) 2016-07-07
MA38253A1 (fr) 2017-02-28
US20150297585A1 (en) 2015-10-22
CN104853755A (zh) 2015-08-19
NI201500078A (es) 2016-02-15
KR20150095681A (ko) 2015-08-21
IL239192A0 (en) 2015-07-30
AR125920A2 (es) 2023-08-23
WO2014090929A1 (fr) 2014-06-19
GT201500143A (es) 2016-01-22
HRP20180333T1 (hr) 2018-04-06
BR112015013675A2 (pt) 2017-07-11
CN104853755B (zh) 2017-08-22
AP2015008498A0 (en) 2015-05-31
UA114016C2 (xx) 2017-04-10
CL2015001615A1 (es) 2015-08-07
EA201590932A1 (ru) 2015-10-30
SI2931276T1 (en) 2018-05-31
GEP201706739B (en) 2017-09-25
LT2931276T (lt) 2018-04-10
ZA201504274B (en) 2016-11-30
CY1120098T1 (el) 2018-12-12
MY171802A (en) 2019-10-30
RU2015122256A (ru) 2017-01-16
EA028300B1 (ru) 2017-10-31
ES2663680T3 (es) 2018-04-16
CA2893468A1 (fr) 2014-06-19
RU2635528C2 (ru) 2017-11-13
AU2013357308A1 (en) 2015-06-18
PH12015501302B1 (en) 2016-02-01
DOP2015000133A (es) 2015-11-30
EP2931276A1 (fr) 2015-10-21
US9211288B2 (en) 2015-12-15
MX362886B (es) 2019-02-22
BR112015013675B1 (pt) 2022-04-26
DK2931276T3 (en) 2018-03-26
HK1212601A1 (en) 2016-06-17
AU2013357308B2 (en) 2017-08-31
PE20151026A1 (es) 2015-07-11
ME03029B (fr) 2018-10-20
AR093939A1 (es) 2015-07-01
EP2931276B1 (fr) 2018-02-21
IL239192B (en) 2019-03-31
MA38253B1 (fr) 2017-10-31
JP2016502990A (ja) 2016-02-01
SG11201504483YA (en) 2015-07-30
ECSP15023182A (es) 2015-12-31
MX2015007269A (es) 2015-08-12
HUE036280T2 (hu) 2018-06-28
PL2931276T3 (pl) 2018-06-29
PH12015501302A1 (en) 2016-02-01
NZ708595A (en) 2019-06-28
RS56949B1 (sr) 2018-05-31
JP6257641B2 (ja) 2018-01-10
PT2931276T (pt) 2018-03-19

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017659A2 (fr)
BR112014017592A2 (fr)
BR112014017646A2 (fr)
BR112014017607A2 (fr)
BR112014017638A2 (fr)
AR092201A1 (fr)
BR112013027865A2 (fr)
BR112014017609A2 (fr)
BR112014017634A2 (fr)
BR112014017644A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014017647A2 (fr)
BR112014013184A8 (fr)
BR112014017623A2 (fr)
BR112014017652A2 (fr)
BR112014017630A2 (fr)
BR112014017627A2 (fr)
BR112014017631A2 (fr)
BR112014017621A2 (fr)
BR112014017622A2 (fr)
BR112014017589A2 (fr)